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DRUG TREATMENT OF INTERMITTENT CLAUDICATION 

A. R. Attard 
Intennittent claudication is a major presenting 
manifestation of chronic obstructive peripheral 
arterial disease of the lower limbs. The goals of 
treatment in the absence of rest pain are relief of 
symptoms, improvement in walking distance and 
prevention of progression of disease. To achieve 
these goals, various treatment strategies are 
available which are influenced by the presence of 
any concurrent illnesses, health expectations and 
life expectancy. Initial treatment modalities are 
therefore conservative and are based on 
symptomatic relief through risk factor 
modification (such as the cessation of smoking), 
exercise and, in some cases, drug therapy. There 
is good clinical evidence that structured exercise 
programmes increase pain free walking distance. 
Smoking cessation may reduce the complications 
of peripheral arterial disease but is of greatest 
benefit in improving graft patency rates in 
patients undergoing by-pass surgery. The 
effectiveness of drug therapy for intennittent 
claudication, however, remains controversial and 
despite numerous clinical trials, many experts are 
not convinced of their value. 
Which drugs? Oxpentifylline (Trental) and 
naftidrofuryl oxalate (Praxilene) are the most 
frequently used and most extensively studied. 
The nicotinic acid derivative inositol nicotinate 
(Hexopal) and anti-platelet drugs are also 
prescribed. What is their mode of action and 
how effecti ve are they? 
Oxpentifylline is thought to alter blood rheology 
by improving the defonnability of red blood cells 
thereby increasing oxygen supply to ischaemic 
tissue; it also reduces plasma fibrinogen and 
decreases platelet adhesion and aggregation. The 
majority of published clinical trials of 
o:tpentifylline show a beneficial effect of the drug 
on claudication distance. Placebo controlled 
studies report an average increase in claudication 
distance of 51 % when compared with placebo. 
However, controversy exists over the magnitude 
of the effect and whether or not any effect 
observed is clinically important. Many trials 
included small numbers of patients and because 
of variations in study design, results cannot be 
pooled in any useful manner. Furthermore, 
progression of disease was not assessed. 
Naftidrofuryl oxalate increases glucose 
consumption at the cellular level, leading to 
increased supply of ATP and decreased lactate 
levels in muscle. It also blocks serotonin induced 
vasoconstriction and platelet aggregation. A 
meta-analysis of several placebo controlled 
studies has shown that over a 3 month period, a 
daily dose of 600mg of naftidrofuryl oxalate 
increased the mean pain free walking distance by 
55% compared to a 25% increase in the placebo 
group. Only one study, at a lower dose of 400mg 
daily, failed to show a difference between 
placebo and active treatment. In common with 
oxpentifylline, naftidrofuryl oxalate seems to 
produce a modest increase in walking distance 
but it is not possible to assess the degree of 
benefit. The effect of the drug on disease 
progression is also unknown. 
There is less evidence to support the use of 
vasodilators in intennittent claudication. In a 
community based study, the nicotinic acid 
derivative inositol nicotinate failed to improve 
objective measurements of claudication, although 
subjective assessments were marginally 
improved. At present, no data is available to 
support the use of this drug in these patients. 
Anti-platelet drugs such as aspmn are now 
routinely used in the secondary prevention of 
cerebrovascular and cardiovascular events in 
patients with a history of myocardial infarction, 
unstable angina, occlusive strokes or transient 
ischaemic attacks. Hence, there has been some 
interest in anti-platelet therapy in patients with 
peripheral arterial disease. To-date, there are no 
published data to detennine whether anti-platelet 
drugs have a beneficial effect on claudication 
distance and disease progression in these 
patients. However, there is recent evidence 
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which supports the use of low dose aspmn to 
reduce the incidence of cerebral and cardiac 
events in patients with peripheral vascular 
disease. At present aspirin is not licensed for 
such use. 
In conclusion, the usefulness of drugs in 
intennittent claudication remains undetennined. 
The benefits seen with oxpentifylline and 
naftidrofuryl oxalate have been marginal and 
may not justify the cost of treatment with these 
drugs. The recent audit on prescribing habits in 
general practice commissioned by the department 
of health in the United Kingdom has classified 
these drugs as "drugs of limited clinical value". 
This suggests that financial savings can be made 
in the health service by cutting their use without 
detriment to patients. This would direct scarce 
resources to more proven treatment modalities. 
In the absence of any other pathology, the patient 
who initially presents with intennittent 
claudication without rest pain should first be 
advised to "stop smoking and keep walking". If 
there is progression of symptoms vascular 
assessment is required. The routine use of drugs 
to improve claudication cannot be recommended 
at present. Further, carefully designed placebo­
controlled studies with large numbers of patients 
and more defined end points are required to 
establish their usefulness or otherwise. 
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